Studying on the progress of cardiotoxicity induced by PD-1/PD-L1 immune checkpoint inhibitors

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Cardiotoxicity (CT) is a serious side effect of anticancer drugs, especially death receptor 1 (PD-1) or death ligand 1 (PD-L1). Immune checkpoint inhibitors (ICIs) have attracted wide attention in recent years. This article describes the progress in studying CT induced by PD-1 and PD-1/PD-L1 ICIs. An overview of PD-1 and PD-1/PD-L1 immune checkpoint inhibitors, their CT manifestations, potential mechanisms, diagnostic and therapeutic methods are presented.

Full Text

Restricted Access

About the authors

Yang Xinyi

University Clinical Hospital No. 1, I.M. Sechenov First Moscow State Medical University (Sechenov University)

Author for correspondence.
Email: xinyiyang@yandex.ru
ORCID iD: 0009-0009-2320-0834

PhD student, Department of Oncology, Reconstructive Surgery and Radiology

Russian Federation, Moscow

I. V. Reshetov

University Clinical Hospital No. 1, I.M. Sechenov First Moscow State Medical University (Sechenov University)

Email: xinyiyang@yandex.ru
Russian Federation, Moscow

M. G. Poltavskaya

University Clinical Hospital No. 1, I.M. Sechenov First Moscow State Medical University (Sechenov University)

Email: xinyiyang@yandex.ru
Russian Federation, Moscow

Yu. S. Agakina

University Clinical Hospital No. 1, I.M. Sechenov First Moscow State Medical University (Sechenov University)

Email: xinyiyang@yandex.ru
Russian Federation, Moscow

T. S. Kulikov

University Clinical Hospital No. 1, I.M. Sechenov First Moscow State Medical University (Sechenov University)

Email: xinyiyang@yandex.ru
Russian Federation, Moscow

References

  1. Beyer A.M., Bonini M.G., Moslehi J. Cancer therapy-induced cardiovascular toxicity: old/new problems and old drugs. Am J Physiol Heart Circ Physiol. 2019;317(1):H164–Н1677. doi: 10.1152/ajpheart.00277.2019.
  2. Xia L., Liu Y., Wang Y.. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions. Oncologist 2019;24(Suppl. 1):S31–S41. doi: 10.1634/theoncologist.2019-IO-S1-s05.
  3. Spallarossa P., Meliota G., Brunelli C., et al. Potential cardiac risk of immune-checkpoint blockade as anticancer treatment: What we know, what we do not know, and what we can do to prevent adverse effects. Med Res Rev. 2018;38(5):1447–68. doi: 10.1002/med.21478.
  4. Inno A., Metro G., Bironzo P., et al. Pathogenesis, clinical manifestations and management of immune checkpoint inhibitors toxicity. Tumori. 2017;103(5):405–21. doi: 10.5301/tj.5000625.
  5. Wu Y., Lin L., Liu X. Identification of PDL1-Related Biomarkers to Select Lung Adenocarcinoma Patients for PD1/PDL1 Inhibitors. Dis Markers. 2020;2020:7291586. doi: 10.1155/2020/7291586.
  6. Khunger A., Battel L., Wadhawan A., et al. New Insights into Mechanisms of Immune Checkpoint Inhibitor-Induced Cardiovascular Toxicity. Curr Oncol Rep. 2020;22(7):65. doi: 10.1007/s11912-020-00925-8.
  7. Lyon A.R., Yousaf N., Battisti N.M.L., et al. Immune checkpoint inhibitors and cardiovascular toxicity. Lancet. Oncol. 2018;19(9):447–58. doi: 10.1016/S1470-2045(18)30457-1.
  8. Boussiotis V.A. Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway. N Engl J Med 2016;375(18):1767–78. doi: 10.1056/NEJMra1514296.
  9. Varricchi G., Galdiero M.R., Marone G., et al. Cardiotoxicity of immune checkpoint inhibitors. ESMO Open. 2017;2(4):e000247. doi: 10.1136/esmoopen-2017-000247.
  10. Varricchi G., Marone G., Mercurio V., et al. Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue. Curr Med Chem. 2018;25(11):1327–39. doi: 10.2174/0929867324666170407125017.
  11. Boutros C., Tarhini A., Routier E., et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol. 2016;13(8):473–86. doi: 10.1038/nrclinonc.2016.58.
  12. Spain L., Walls G., Julve M., et al. Neurotoxicity from immunecheckpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature. Ann. Oncol. 2017;28(2):377–85. doi: 10.1093/annonc/mdw558.
  13. Michot J.M., Bigenwald C., Champiat S., et al. Immune–related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer.2016;54:139–48.
  14. Zhang J.C., Chen W.D., Alvarez J.B., et al. Cancer immune checkpoint blockade therapy and its associated autoimmune cardiotoxicity. Acta Pharmacol. Sinica. 2018;39(11):1693–98. doi: 10.1038/s41401-018-0062-2.
  15. Johnson D.B., Balko J.M., Compton M.L., et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375:1749–55. doi: 10.1056/NEJMoa1609214.
  16. Choi J., Lee S.Y. Clinical Characteristics and Treatment of ImmuneRelated Adverse Events of Immune Checkpoint Inhibitors. Immune Netw. 2020;20(1):e9. doi: 10.4110/in.2020.20.e9.
  17. Zhang C., Liu Y., Wang H., et al. Real-world Cardiovascular toxicity of immune checkpoint inhibitors in cancer patients: a retrospective controlled cohort study. Scientific Reports. 2024;14(5):76829. doi: 10.1038/s41598-024-76829-5.
  18. Konala V.M., Adapa S., Aronow W.S. Immune Checkpoint InhibitorsRelated Cardiotoxicity. Am J Ther. 2020;27(6):e591–e598. doi: 10.1097/MJT.0000000000000988.
  19. Zhou Y.W., Zhu Y.J., Wang M.N., et al. Immune Checkpoint Inhibitor-Associated Cardiotoxicity: Current Understanding on Its Mechanism, Diagnosis and Management. Front Pharmacol. 2019;10:1350. doi: 10.3389/ fphar.2019.01350.
  20. Baraibar I., Melero I., Ponz-Sarvise M., et al. Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer. Drug Saf. 2019;42(2):281–94. doi: 10.1007/s40264-018-0774-8.
  21. Chen D.Y., Huang W.K., Chien-Chia Wu V., et al. Cardiovascular toxicity of immune checkpoint inhibitors in cancer patients: A review when cardiology meets immuno-oncology. J Formos Med Assoc. 2020;119(10):1461–75. doi: 10.1016/j.jfma.2019.07.025.
  22. Palaskas N., Lopez-Mattei J., Durand J.B., et al. Immune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and Treatment. J Am Heart Assoc. 2020;9(2):e013757. doi: 10.1161/JAHA.119.013757.
  23. Raikhelkar J., Uriel N. Immune checkpoint inhibitor myocarditis. Curr Opin Cardiol. 2019;34(3):303–6. doi: 10.1097/HCO.0000000000000622.
  24. Peleg Hasson S., Salwen B., Sivan A., et al. Re-introducing immunotherapy in patients surviving immune checkpoint inhibitors-mediated myocarditis. Clin Res Cardiol. 2020;110(1):50–60. doi: 10.1007/s00392-020-01648-3.
  25. Slawinski G., Wrona A., Dabrowska-Kugacka A., et al. Immune Checkpoint Inhibitors and Cardiac Toxicity in Patients Treated for Non-Small Lung Cancer: A Review. Int J Mol Sci. 2020;21(19):7195. doi: 10.3390/ijms21197195.
  26. Mahmood S.S., Fradley M.G., Cohen J.V., et al. Myocarditis in Patients Treated With Immune Checkpoint Inhibitors. J Am Coll Cardiol. 2018;71(16):1755–64. doi: 10.1016/j.jacc.2018.02.037.
  27. Altan M., Toki M.I., Gettinger S.N., et al. Immune Checkpoint Inhibitor-Associated Pericarditis. J Thorac Oncol. 2019;14(6):1102–8. doi: 10.1016/j.jtho.2019.02.026.
  28. Trontzas I.P., Vathiotis I.A., Kyriakoulis K.G., et al. Takotsubo Cardiomyopathy in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Summary of Included Cases. Cancers (Basel). 2023;15(9):2637. doi: 10.3390/cancers15092637.
  29. Shalata W., Abu-Salman A., Steckbeck R., et al. Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: A Systematic Review. Cancers (Basel). 2021;13(20):5218. doi: 10.3390/cancers13205218.
  30. Sarocchi M., Grossi F., Arboscello E., et al. Serial Troponin for Early Detection of Nivolumab Cardiotoxicity in Advanced Non-Small Cell Lung Cancer Patients. Oncologist. 2018;23(8):936–42. doi: 10.1634/theoncologist.2017-0452.
  31. Martin Huertas R., Saavedra Serrano C., Perna C., et al. Cardiac toxicity of immune-checkpoint inhibitors: A clinical case of nivolumab-induced myocarditis and review of the evidence and new challenges. Cancer Manag Res. 2019;11:4541–8. doi: 10.2147/CMAR.S185202.
  32. Zlotoff D.A., Hassan M.Z.O., Zafar A., et al. Electrocardiographic features of immune checkpoint inhibitor associated myocarditis. J Immunother Cancer. 2021;9(3):e002007. doi: 10.1136/jitc-2020-002007.
  33. Poto R., Troiani T., Criscuolo G., et al. Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events. Front Immunol. 2022;13:804597. doi: 10.3389/fimmu. 2022.804597.
  34. Ganesh S., Zhong P., Zhou X. Cardiotoxicity induced by immune checkpoint inhibitor: The complete insight into mechanisms, monitoring, diagnosis, and treatment. Front Cardiovasc Med. 2022;9:997660. doi: 10.3389/fcvm.2022.997660.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Bionika Media